RecruitingNCT07216469
A Study Of Myocardial Stiffness In Amyloidosis With Magnetic Resonance Elastography
Myocardial Stiffness in Amyloidosis by Magnetic Resonance Elastography - AMREloid Study
Sponsor
Mayo Clinic
Enrollment
20 participants
Start Date
Oct 14, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This is a prospective case control study to determine the feasibility and utility of myocardial stiffness assessment by cardiac magnetic resonance elastography (MRE) in patients with cardiac amyloidosis.
Eligibility
Min Age: 20 Years
Inclusion Criteria12
- Subjects are eligible to be included in the study if all the following criteria apply:
- Adult, age 20 and greater
- Subject is clinically stable without cardiovascular-related hospitalizations within 2 weeks prior to enrollment as assessed by the investigators
- Subject is able to provide written informed consent and is willing and able to complete study procedures
- Subject must meet criteria for either ATTR cardiac amyloidosis or AL cardiac amyloidosis from review of medical records as specified below:
- a. ATTR cardiac amyloidosis based on meeting all the following criteria:
- i. Diagnosis of amyloidosis within ten years prior to study screening
- ii. Transthyretin amyloid deposits in cardiac tissue OR Technetium (99mTc) bone scintigraphy with grade 2 or 3 cardiac uptake OR Transthyretin amyloid deposits in non-cardiac tissue with echocardiographic evidence of cardiac involvement or an end-diastolic mean wall thickness > 12 mm OR Transthyretin amyloid deposits in non-cardiac tissue with cardiac MRI diagnostic of amyloidosis OR Clinical diagnosis of cardiac amyloidosis by the clinical provider
- b. AL cardiac amyloidosis based on meeting all the following criteria:
- i. Diagnosis of amyloidosis within ten years prior to study screening
- ii. Histopathologic diagnosis of amyloidosis with AL protein identification
- iii. Cardiac involvement as defined by: Amyloid deposits in cardiac deposits OR Echocardiography with an end-diastolic mean wall thickness > 12 mm in the absence of other causes OR Elevated NT-proBNP (>332 ng/L) in the absence of renal failure or atrial fibrillation OR Cardiac MRI diagnostic of amyloidosis OR Clinical diagnosis of cardiac amyloidosis by the clinical provider
Exclusion Criteria2
- Patients are ineligible to be included in the study if any of the following criteria apply:
- \. Unable to consent or unable to complete all study procedures 2. Unable to ambulate for 6 minutes (confirmed at study coordinator visit) 3. Unable to maintain in supine position for 30 minutes 4. Unable to maintain breath-holding for 10 seconds (confirmed at study coordinator visit) 5. Contraindications for safe MRI scanning (e.g., uncontrolled claustrophobia, cochlear implant, implanted neural stimulator) 6. Presence of implantable cardiac pacemaker or defibrillator 7. History of complex congenital heart disease, prosthetic valves, prosthesis in the main pulmonary artery or ascending thoracic aorta 8. Significant artifact from prior MRI studies 9. Pregnant or breast-feeding women 10. Weight equal to or greater than 155 kg 11. In the judgment of the investigator, has clinically relevant ongoing medical condition or laboratory abnormalities or other condition that might jeopardize the participants safety, increase the participants risk from participation, interfere with the study, or confirmed study results
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TESTMagnetic Resonance Elastography (MRE)
Patients will undergo a cardiac MRI with the addition of continuous free-breathing and breath-held MRE sequences.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07216469
Related Trials
NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis
NCT062517781 location
Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
NCT069748771 location
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
NCT057584931 location
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT0656389598 locations
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
NCT0708164618 locations